ArticleActa oncologica (Stockholm, Sweden)2026
Increasing survival disparity between children, adolescents, and young adults with osteosarcoma or Ewing sarcoma of bone from 1990 to 2024: a population-based cohort study.
Article in Acta oncologica (Stockholm, Sweden), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Osteosarcoma Across the Age Spectrum: Why Outcomes Diverge and Trials Must Adapt.Journal of clinical medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
background and purposeBone sarcomas are important contributors to early-life cancer mortality and morbidity. Optimisation of treatment regimens has improved survival, but the survival disparity between children, adolescents and young adults has widened. Population-based studies are needed to understand and address these disparities. This is the first comprehensive study of early-life bone sarcomas in Denmark. Patient/material and methods: We combined population-wide data from national registers from 1990 to 2024 with clinical data from patient records. We calculated age-standardised incidence rates, 5-year relative survival rates stratified by several clinical factors, and Aalen-Johansen estimators for relapse/progression and death within 5 years.
resultsA total of 578 patients under 40 years of age were diagnosed with either osteosarcoma (n = 336) or Ewing sarcoma of bone (n = 242) in Denmark between 1990 and 2024. Five-year relative survival improved for patients aged 0-24 years but stagnated for those aged 25-39 years. We observed age-dependent differences in the distribution of tumours and in relative survival across anatomical sites, tumour sizes, and treatment regimens. Metastatic disease or a tumour diameter of > 8 cm reduced relative survival by 19 to 45 percentage points.
interpretationSurvival disparities between children, adolescents, and young adults with bone sarcomas are likely multifactorial. Age-dependent differences in the distribution of tumours across anatomical sites and in tumour size appear to play a role. The incidence of and survival from relapse/progression also appear to favour younger patients. Including patients in international, joint paediatric-adult treatment protocols remains a high priority.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.